ASPM overexpression enhances cellular proliferation and migration and predicts worse prognosis for papillary renal cell carcinoma

Li, N.; Chu, Jianfeng; Hu, Keyao; Zhang, Haiying; Li, N; Chu, Junhao; Ky, Hu; Hy, Zhang

doi:10.1007/s12038-023-00340-8

Cited by 2 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…68 ASPM is a centrosomal protein that contributes to mitotic spindle formation, orientation, cytokines, neurogenesis, and brain development. 69,70 During metaphase, ASPM is located at the spindle poles, whereas during interphase, it is found in the nucleus and centrosome. Moreover, the ASPM localization to the midbody during cytokinesis suggests that it participates in abscission.…”

Section: Hmmrmentioning

confidence: 99%

“…73 However, in the last decade, this gene has also been implicated in the progression of a variety of malignancies, 71 including glioblastoma, cancers of the prostate, breast, bladder, 74 and epithelial ovarian, 71,73 as well as endometrial, 69 hepatocellular, 75 lung, 76 and papillary renal cell carcinoma. 70 ASMP has been recognized by several authors as a significant prognostic gene in cases of BC. The study of RNA sequencing (RNA-seq) data from 116 BC tissues lacking expression of ER, PR, and HER2, as well as 113 normal tissues obtained from the TCGA, provides more support for the aforementioned statement.…”

Section: Hmmrmentioning

confidence: 99%

See 1 more Smart Citation

Identification of prognostic biomarkers of invasive ductal carcinoma by an integrated bioinformatics approach

Marrugo-Padilla,

Márquez-Lázaro,

Álviz-Amador

2023

F1000Res

View full text Add to dashboard Cite

Background: Invasive ductal carcinoma (IDC) is the most common type of breast cancer (BC) worldwide. Nowadays, due to its heterogeneity and high capacity for metastasis, it is necessary to discover novel diagnostic and prognostic biomarkers. Therefore, this study aimed to identify novel candidate prognostic genes for IDC using an integrated bioinformatics approach. Methods: Three expression profile data sets were obtained from GEO (GSE29044, GSE3229, and GSE21422), from which differentially expressed genes (DEGs) were extracted for comparative transcriptome analysis of experimental groups (IDC versus control). Next, STRING was utilized to construct a protein interaction network with the shared DEGs, and MCODE and cytoHubba were used to identify the hub genes, which were then characterized using functional enrichment analysis in DAVID and KEGG. Finally, using the Kaplan-Meier tracer database, we determined the correlation between the expression of hub genes and overall survival in BC. Results: We identified seven hub genes (Kinesin-like protein KIF23 [KIF23], abnormal spindle-like microcephaly [ASPM]-associated protein [ASPMAP], Aurora kinase A [AURKA], Rac GTPase-activating protein 1 [RACGAP1], centromere protein F [CENPF], hyaluronan-mediated motility receptor [HMMR], and protein regulator of cytokinesis 1 [PRC1]), which were abundant in microtubule binding and tubulin binding, pathways linked to fundamental cellular structures including the mitotic spindle, spindle, microtubule, and spindle pole. The role of these genes in the pathophysiology of IDC is not yet well characterized; however, they have been associated with other common types of BC, modulating pathways such as Wnt/β-catenin, the epithelial-to-mesenchymal transition (EMT) process, chromosomal instability (CIN), PI3K/AKT/mTOR, and BRCA1 and BRCA2, playing an important role in its progression and being associated with a poor prognosis, thus representing a way to improve our understanding of the process of tumorigenesis and the underlying molecular events of IDC. Conclusions: Genes identified may lead to the discovery of new prognostic targets for IDC.

show abstract

Section: Hmmrmentioning

confidence: 99%

Section: Hmmrmentioning

confidence: 99%

Identification of prognostic biomarkers of invasive ductal carcinoma by an integrated bioinformatics approach

Marrugo-Padilla,

Márquez-Lázaro,

Álviz-Amador

2023

F1000Res

View full text Add to dashboard Cite

show abstract

CAR memory–like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancer

Tarannum,

Dinh,

Vergara

et al. 2024

Sci. Adv.

View full text Add to dashboard Cite

Epithelial ovarian cancer (EOC) remains one of the most lethal gynecological cancers. Cytokine-induced memory–like (CIML) natural killer (NK) cells have shown promising results in preclinical and early-phase clinical trials. In the current study, CIML NK cells demonstrated superior antitumor responses against a panel of EOC cell lines, increased expression of activation receptors, and up-regulation of genes involved in cell cycle/proliferation and down-regulation of inhibitory/suppressive genes. CIML NK cells transduced with a chimeric antigen receptor (CAR) targeting the membrane-proximal domain of mesothelin (MSLN) further improved the antitumor responses against MSLN-expressing EOC cells and patient-derived xenograft tumor cells. CAR arming of the CIML NK cells subtanstially reduced their dysfunction in patient-derived ascites fluid with transcriptomic changes related to altered metabolism and tonic signaling as potential mechanisms. Lastly, the adoptive transfer of MSLN-CAR CIML NK cells demonstrated remarkable inhibition of tumor growth and prevented metastatic spread in xenograft mice, supporting their potential as an effective therapeutic strategy in EOC.

show abstract

ASPM overexpression enhances cellular proliferation and migration and predicts worse prognosis for papillary renal cell carcinoma

Cited by 2 publications

References 33 publications

Identification of prognostic biomarkers of invasive ductal carcinoma by an integrated bioinformatics approach

Identification of prognostic biomarkers of invasive ductal carcinoma by an integrated bioinformatics approach

CAR memory–like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancer

Contact Info

Product

Resources

About